Natural History Studies for Rare Disease Product Development: Orphan Products Research Project Grant (R01)
The objective of FDA's Orphan Products Natural History Grants Program is to support studies that advance rare disease medical product development through characterization of the natural history of rare diseases/conditions, identification of genotypic and phenotypic subpopulations, and development
and/or validation of clinical outcome measures, biomarkers and/or companion diagnostics.
The ultimate goal of these natural history studies is to support clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy.
FDA provides grants for natural history studies that will either assist or substantially contribute to market approval of these products.
Applicants must include in the application's Background and Significance section documentation to support that the estimated prevalence of the orphan disease or condition in the United States (US) is less than 200,000 (or in the case of a vaccine or diagnostic, information to support that the product will be administered to fewer than 200,000 people in the US per year), and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.
Additional information may be required upon request, for example, regarding population estimate and rationale.
The ultimate goal of these natural history studies is to support clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy.
FDA provides grants for natural history studies that will either assist or substantially contribute to market approval of these products.
Applicants must include in the application's Background and Significance section documentation to support that the estimated prevalence of the orphan disease or condition in the United States (US) is less than 200,000 (or in the case of a vaccine or diagnostic, information to support that the product will be administered to fewer than 200,000 people in the US per year), and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.
Additional information may be required upon request, for example, regarding population estimate and rationale.
Who's Eligible
Obtain Full Opportunity Text:
Full Announcemnet of RFA-FD-16-043
Additional Information of Eligibility:
Minority entities are the only applicants that are eligible to apply for this grant opportunity.
NIDILRR’s FI Projects grant opportunity for minority serving institutions is intended to improve the capacity of minority entities to conduct high quality disability and rehabilitation research by limiting eligibility for this opportunity to minority entities and Indian tribes.
Section 21(b)(2)(A) of the Act authorizes NIDILRR to make awards to minority entities and Indian tribes to carry out activities authorized under Title II of the Act.
A minority entity is defined as a historically black college or university (a part B institution, as defined in section 322(2) of the Higher Education Act of 1965, as amended), a Hispanic-serving institution of higher education, an American Indian tribal college or university, or another institution of higher education whose minority student enrollment is at least 50 percent.
Foreign entities are not eligible to compete for, or receive, awards made under this announcement.
Full Opportunity Web Address:
Contact:
Agency Email Description:
Agency Email:
daniel.lukash@fda.hhs.gov
Date Posted:
2016-04-15
Application Due Date:
2018-10-15
Archive Date:
2018-11-14
Social Entrepreneurship
Spotlight
The Social Innovators of 2014
For 2014, the Schwab Foundation for Social Entrepreneurship has recognized 37 individuals for their outstanding work in the field of social enterprise.
Learn How to Identify and Avoid Grant Scams
